2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof wherein:

R 1 is selected from H and alkyl C1-C3 ;

R 2 is selected from H, alkyl C1-C3 , and halo;

R 3 is selected from H, OH, alkyl C1-C6 , -alkylene C1-C6 -OH, -alkylene C1-C6 -phenyl (optionally substituted with a halo), and -alkylene C1-C6 -C(O)NH 2 ;

R 4 is selected from H, halo, alkyl C1-C6 , and —O-alkyl C1-C6 ; or,

R 3 and R 4 , together with the atoms to which they are bound, form a five or six membered lactam;

R 5 and R 6 are each independently selected from H, halo, alkyl C1-C6 , and —O-alkyl C1-C6 , or

R 5 and R 6 together with the aryl to which they are attached form a napthalene;

R 7 is selected from alkyl C1-C6 , —O-alkyl C1-C6 , halo, —N—R 19 R 19 , and —O-alkylene C1-C6 -halo 1-3 ;

R 8 is selected from H, halo, and alkyl C1-C6 ;

one of R 9 and R 10 is selected from -alkylene C1-C6 -SO 2 -alkyl C1-C6 ,

—NR 19 -alkylene C0-C6 -C(O)-alkylene C0-C6 -NR 22 R 23 ,

—O-alkylene C0-C6 (optionally substituted with —OH)—NR 22 R 23 ,

and

the other of R 9 and R 10 is selected from H, alkyl C1-C6 , —O-alkyl C1-C6 , and halo;

wherein Het1 and Het2 are each independently a five or six membered heterocyclic ring having an N atom and optionally one or two additional heteroatoms selected from N and O, and

each R 14 is independently selected from H, OH, halo, alkyl C1-C6 , —O-alkyl C1-C6 , -cyclopropyl, —C(O)-alkyl C1-C6 , SO 2 -alkyl C1-C6 , —(CH 2 ) 1-4 -halo, and —(CH 2 ) 1-4 —SO 2 -alkyl C1-C6 ;

or

R 9 and R 10 , together with the atoms to which they are attached form a five, six, or seven-membered heterocyclic ring containing one or two N atom and the remainder C atoms, wherein at least one N atom is substituted with R 15 , and the C atoms of the heterocyclic ring are optionally substituted with one or more groups selected from R 16 and (R 19 ) 1-2 ;

wherein R 15 is selected from H, -alkyl C1-C4 , -alkylene C1-C4 -halo, —C(O)-alkylene C0-C6 -NR 22 R 23 , —C(O)-alkyl C1-C6 , -alkylene C1-C4 -NR 22 R 23 , -alkylene C1-C4 -C(O)—NR 23 R 23 ,

—C(O)-alkylene C1-C4 -O-alkyl C1-C6 , —C(O)-pyrrolidine, and —C(O)-pyrrolidine-alkyl C1-C6 ;

R 16 is selected from H and ═O; and,

each R 19 is independently selected from H and alkyl C1-C6 ;

R 22 is selected from H, alkyl C1-C6 , —O-alkyl C1-C6 , -alkylene C1-C6 -O-alkyl C1-C6 , —(CH 2 ) 2-4 -halo, and —(CH 2 ) 2-4 —SO 2 -alkyl C1-C6 ; and,

R 23 is selected from H, alkyl C1-C6 , —(CH 2 ) 2-4 -halo, and —(CH 2 ) 2-4 -SO 2 alkyl C1-C6 ; or

R 22 and R 23 combine to form a four, five, or six membered, heterocyclic ring containing the N atom to which they are attached and optionally an additional heteroatom selected from N and O, wherein the ring is optionally substituted with —OH or -alkyl C1-C6 .

2. The compound of claim 1 , wherein R 4 , R 5 , and R 6 are each independently selected from H and halo.

3. The compound of claim 1 , wherein R 3 is H.

4. The compound of claim 1 , wherein R 3 is methyl.

5. The compound of claim 1 , wherein R 7 is —O-alkyl C1-C6 .

6. The compound of claim 1 , wherein R 7 is —O-methyl.

7. The compound of claim 1 , wherein R 8 is H.

8. The compound of claim 1 , wherein R 10 is H and R 9 is selected from -alkylene C1-C6 -SO 2 -alkyl C1-C6 , —NR 19 -alkylene C0-C6 -C(O)-alkylene C0-C6 -NR 22 R 23 , —O-alkylene C0-C6 (optionally substituted with —OH)—NR 22 R 23 ,

9. The compound of claim 1 , wherein R 10 is H and R 9 is selected from

10. The compound of claim 1 , wherein R 9 and R 10 , together with the atoms to which they are attached form a five or six-membered heterocyclic ring selected from

11. The compound of claim 1 , having formula (Ia):

12. The compound of claim 1 , having formula (Ib):

13. The compound of claim 1 , having formula (Ic):

14. The compound of claim 1 , having formula (Id):

15. The compound of claim 1 , having formula (Ie):

16. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

17. A compound selected from the following:

or a pharmaceutically acceptable salt thereof.